文献速递肿瘤 PET/CT

18F-FLT与18F-FDG PET/CT早期预测瑞戈非尼治疗难治性转移性结直肠癌疗效

3'-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-04-30

结果显示18F-FDG PET/CT的PERCIST标准与无进展生存和总生存显著相关,而18F-FLT摄取变化仅与无进展生存略有相关。

要点

  • 18F-FDG PET/CT的PERCIST可早期预测瑞戈非尼治疗mCRC的PFS和OS。
  • 18F-FLT PET/CT摄取变化仅与PFS略有相关,与OS无关。
  • CT与18F-FLT PET/CT疗效评估不一致率达70.5%。

核心结论

  • 生存结局与基于18F-FDG PET/CT的PERCIST显著相关,而18F-FLT摄取变化仅与PFS略有相关。
  • 18F-FDG PET/CT可作为影像生物标志物早期预测mCRC患者接受瑞戈非尼的临床结局。

研究设计与样本

  • 每8周评估标准解剖学疗效,并在瑞戈非尼治疗前及第21天行18F-FLT和18F-FDG PET/CT。
  • 符合方案分析纳入61例患者。

主要发现

  • 61例可分析患者中,完全缓解未观察到,部分缓解8.2%(n=5),疾病稳定67.2%(n=41),疾病进展24.6%(n=15)。
  • 客观缓解率为8.2%,疾病控制率为75.4%。
  • 5例缓解者(8.2%)和13例非缓解者(21.3%)符合CT和18F-FLT PET/CT标准(缓解者最大标准化摄取值下降≥10.6%)。
  • 中位随访8.9个月时,中位无进展生存期为3.6个月(95%CI 3.34-3.80个月),中位总生存期为8.5个月(95%CI 6.95-10.10个月)。

关键数值与推荐

  • 18F-FLT PET/CT缓解标准为最大标准化摄取值下降≥10.6%。
  • 18F-FDG PET/CT采用PERCIST标准评估代谢缓解。

临床怎么用

  • 对于标准治疗失败的mCRC患者,瑞戈非尼治疗早期可考虑行18F-FDG PET/CT及PERCIST评估以预测生存结局。
  • 18F-FLT PET/CT对早期预测生存结局的价值有限,仅与PFS略有相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to evaluate the value of 3'-deoxy-3'-18F-fluorothymidine (18F-FLT) and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for early prediction of standard anatomic response and survival outcomes in patients with metastatic colorectal cancer (mCRC) receiving Regorafenib. METHODS: Sixty-eight patients with mCRC refractory to standard cytotoxic chemotherapy were enrolled and received Regorafenib (160 mg/day on days 1-21, following a 7-day break). Standard anatomical response was evaluated every 8 weeks. Both scans were performed before and on day 21 of Regorafenib. RESULTS: Of the 61 patients included in per-protocol analysis, complete response was not observed, but partial response was observed in 8.2% (n = 5), stable disease in 67.2% (n = 41), and progressive disease in 24.6% (n = 15). The objective response rate was 8.2% and disease control rate 75.4%. Five responders (8.2%) and 13 non-responders (21.3%) met the CT and 18F-FLT PET/CT criteria (maximum standardized uptake value decrease ≥ 10.6% for responders). Forty-three (70.5%) exhibited discordant responses on CT and 18F-FLT PET/CT (McNemar test, P < 0.001). At a median follow-up of 8.9 months, median progression-free survival (PFS) and median overall survival (OS) were 3.6 months (95% confidence interval [CI], 3.34-3.80 months) and 8.5 months (95% CI, 6.95-10.10 months), respectively. Comparison of PFS and OS according to 18F-FLT PET/CT response revealed slightly longer PFS (P = 0.015) in responders, but the correlation with OS was not significant. The PET Response Criteria in Solid Tumours (PERCIST) of 18F-FDG PET/CT revealed differences in PFS and OS between partial metabolic response (PMR) and non-PMR (P = 0.048 and P = 0.014, respectively), and between progressive metabolic disease (PMD) and non-PMD (P = 0.189 and P = 0.007, respectively). CONCLUSIONS: Survival outcome was significantly associated with PERCIST using 18F-FDG PET/CT but the change of 18F-FLT uptake was only slightly associated with PFS. 18F-FDG PET/CT can be used as imaging biomarker to predict clinical outcomes early in patients with mCRC receiving Regorafenib.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kim JE, Chae SY, Kim JH, et al. 3'-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. Eur J Nucl Med Mol Imaging. 2019. PMID: 31041456. doi:10.1007/s00259-019-04330-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。